Global Health Technologies Coalition Global Health Technologies Coalition
  • Why R&D
  • R&D Facts
  • In Your State
  • Solutions
  • Breakthroughs Blog
  • News & Events
  • Resources
  • About Us
Stay Informed

Global health R&D delivers forMinnesota

Map
Minnesota
Select a new state
Select a State
Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois
Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana
Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island
South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming

US government investment in global health R&D has delivered

$32.8 million
to Minnesota research institutions
400+ new jobs
for Minnesota
Minnesota

Neglected diseases in Minnesota

Chikungunya cases
Chikungunya cases
59
Dengue cases
Dengue cases
104
HIV diagnoses
HIV diagnoses
2854
Malaria cases
Malaria cases
358
Tuberculosis cases
Tuberculosis cases
1422
West Nile cases
West Nile cases
286
Zika cases
Zika cases
74
Minnesota's top USG-funded global health R&D institutions

Minnesota's top USG-funded global health R&D institutions

University of Minnesota
$32.8 million
Minnesota industry in global health R&D

Minnesota industry in global health R&D

3M
Location(s): Saint Paul
Beckman Coulter
Location(s): Chaska
GeneSegue
Location(s): Minnetonka
Medical Avatar
Location(s): Minneapolis
Medisyn Technologies
Location(s): Minnetonka
Medtronic
Location(s): Minneapolis

Minnesota's top areas of global health R&D by USG funding

26.9%
HIV/AIDS
25.2%
Malaria
16%
Tuberculosis
24.7%
Salmonella infections
2.3%
Other
Bacterial pneumonia & meningitis
Ebola/viral hemorrhagic fevers
Global health R&D at work in Minnesota
Global health R&D at work in Minnesota

Researchers at the University of Minnesota Medical School are working to unlock why antiretroviral therapies are unable to completely shut down HIV production in cells in certain parts of the body. According to their research, nearly 99 percent of these HIV-infected cells are found in tissue in the lymph nodes, spleen, and gastrointestinal tract. This reservoir of latently infected cells can reactivate if therapy is interrupted, posing a major challenge to curing the disease. Their key finding was that these cells are associated with lower concentrations of drugs in these tissues. A next step is to understand why current treatments do not reach adequate levels in lymphoid tissue. This knowledge could lead to development of more effective treatments for HIV or even a cure for AIDS. Globally, more than 36 million people are living with HIV.

Download PDF
Map
Select a new state
Footnotes
  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: PATH/Evelyn Hockstein
Close
advancing innovation to save lives

© 2009–2021, PATH, as secretariat of the Global Health Technologies Coalition.

Site managed by A3CS

  • Stay Informed
  • Join Us
  • Contact Us
  • GHTC Member Log In